D61.1
Drug-induced aplastic anemia
Clinical Classification Guidelines
Use Additional Code
- code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
Medical Intelligence & Overview
Drug-induced aplastic anemia is a rare but serious condition where a medication causes the bone marrow to stop producing enough blood cells. This can lead to symptoms like fatigue, increased risk of infections, and easy bruising or bleeding. Recognizing this condition early is crucial for effective management and treatment.
Causes & Symptoms
Clinical Causes: Certain medications such as some antibiotics, antihypertensives, and antiepileptics Chemotherapy drugs used to treat cancer Nonsteroidal anti-inflammatory drugs (NSAIDs)
Key Symptoms: Fatigue and weakness Increased susceptibility to infections Unusual or excessive bleeding or bruising Pale skin Shortness of breath Fever or chills Rapid heart rate
Diagnostic & Treatment
Diagnosis Path: Diagnosing drug-induced aplastic anemia involves a medical evaluation that includes blood tests to check blood cell counts and bone marrow analysis to assess cell production. A detailed medical history focusing on recent medication use helps identify potential causes. Doctors may also perform additional tests to rule out other blood disorders or underlying conditions.
Treatment Protocols: Treatment primarily aims to stop exposure to the offending medication and support blood cell production. Approaches include:
Clinical Advice & FAQs
Billing Guidance
Is D61.1 a billable ICD-10 code?
Yes, D61.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D61.1?
Clinical documentation must specify the nature of Drug-induced aplastic anemia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference